ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
mutation as a combination biomarker in predicting response to ICT in CheckMate275 and IMvigor210. Combination of the two biomarkers in baseline tumor tissues suggested improved OS compared to either single biomarker. Cumulatively, this study revealed that the combination of CXCL13 plus ARID1A may improve prediction capability for patients receiving ICT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A retrospective analysis identified mutations in ARID1A in tumor tissues and expression of the chemokine CXCL13 as predictive biomarkers for ICT (170).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [170]
In the citing paper
“Importantly, the combination of ARID1A mutation plus CXCL13 showed improved predictive capacity compared with either of the single biomarkers alone (170).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [170]
In the citing paper
“Preclinical studies demonstrated association of ARID1A and CXCL13 with antitumor immunity in mice (170).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [170]
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 4,935 · cited 1×
“The filtered mutation data were analyzed using the R package maftools (32).”
MethodIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.052 · Cited by 3,725
Self-citationRosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Comprehensive molecular characterization of urothelial bladder carcinoma
Weinstein, J. N., Akbani, R., Broom, B. M., Wang, W., Verhaak, R. G. W., Liu, W., Ju, Z., Motter, T., Peng, B., Ryan, M., et al. (2014) · Nature · doi:10.1038/nature12965 · Cited by 3,142
Self-citationComprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Self-citation
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Self-citationThe Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Self-citationEnhancing anti-tumour efficacy with immunotherapy combinations
Meric-Bernstam, F., Larkin, J., Tabernero, J., & Bonini, C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32598-8 · Cited by 409
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances
Zhao, L., Jin, S., Wang, S., Zhang, Z., Wang, X., Chen, Z., Wang, X., Huang, S., Zhang, D., & Wu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01947-5 · Cited by 218
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Phillips, D., Matusiak, M., Gutierrez, B. R., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., Fling, S. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26974-6 · Cited by 218
“73 Goswami, S. et al. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med 12, doi:10.1126/scitranslmed.abc4220 (2020).”
BackgroundInfluentialGroeneveld, C. S., Fontugne, J., Cabel, L., Bernard-Pierrot, I., Radvanyi, F., Allory, Y., & de Reyniès, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.036 · Cited by 160
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
Maxwell, M. B., Hom, M. S., Yi, J., Li, S., Rivera, S. A., Yu, J., Burns, M. J., McRae, H. M., Stevenson, B. T., Coakley, K. E., et al. (2024) · Cell · doi:10.1016/j.cell.2024.04.025 · Cited by 156
Next-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 127
Self-citationCXCL13-CXCR5 axis: Regulation in inflammatory diseases and cancer
Wang, B., Wang, M., Ao, D., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188799 · Cited by 127
Wang, L., Sfakianos, J. P., Beaumont, K. G., Akturk, G., Horowitz, A., Sebra, R. P., Farkas, A. M., Gnjatic, S., Hake, A., Izadmehr, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4574 · Cited by 97
Self-citationRaufaste-Cazavieille, V., Santiago, R., & Droit, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.962743 · Cited by 110
Goubet, A.-G., Lordello, L., Alves Costa Silva, C., Peguillet, I., Gazzano, M., Mbogning-Fonkou, M. D., Thelemaque, C., Lebacle, C., Thibault, C., Audenet, F., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0201 · Cited by 86
Tsukamoto, H., Komohara, Y., Tomita, Y., Miura, Y., Motoshima, T., Imamura, K., Kimura, T., Ikeda, T., Fujiwara, Y., Yano, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205378119 · Cited by 87
Immune Aging and Immunotherapy in Cancer
Kaiser, M., Semeraro, M. D., Herrmann, M., Absenger, G., Gerger, A., & Renner, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137016 · Cited by 84
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
Hsieh, C.-H., Jian, C.-Z., Lin, L., Low, G.-S., Ou, P.-Y., Hsu, C., & Ou, D. (2022) · Cancers · doi:10.3390/cancers14020294 · Cited by 73
“CXCL13 Anti-PD-1 Anti-PD-L1 Metastatic urothelial carcinoma and bladder cancer Whole-exome sequencing data analysis TCGA analysis CheckMate275 (n = 270) IMvigor210 (n = 310) Favorable CXCL13 expression plus ARID1A mutation work together to predict a favorable response to anti-PD-1 blockade [109].”
BackgroundMethodTertiary lymphoid structures and cancer immunotherapy: From bench to bedside
Peyraud, F., Guégan, J., Vanhersecke, L., Brunet, M., Teyssonneau, D., Palmieri, L., Bessede, A., & Italiano, A. (2025) · Med · doi:10.1016/j.medj.2024.10.023 · Cited by 81
Gao, S., Liu, S., Wang, G., & Zhou, G. (2021) · Life · doi:10.3390/life11121282 · Cited by 83
Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?
Fridman, W. H., Sibéril, S., Pupier, G., Soussan, S., & Sautès‐Fridman, C. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101703 · Cited by 70
Opportunities and challenges of targeting cGAS–STING in cancer
Lu, C., Wang, W., & Fu, Y. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00894-9 · Cited by 79
“Similarly, ARID1A mutations, often found in patients with cancer who respond well to ICB 81–83 , generate R-loop-derived cytosolic DNA that activates the cGAS–STING–IFN axis, thereby increasing CD8 + T cell infiltration 47 .”
Palomero, J., Panisello, C., Lozano-Rabella, M., Tirtakasuma, R., Díaz-Gómez, J., Grases, D., Pasamar, H., Arregui, L., Duch, E. D., Guerra, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005443 · Cited by 77
Sun, D., Lu, T., Zhu, Y., Wo, Y., Liu, Q., Liu, S., Li, H., & Hou, H. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00208-9 · Cited by 60
Zhu, Y., Yan, C., Wang, X., Xu, Z., Lv, J., Xu, X., Yu, W., Zhou, M., & Yue, L. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.2011643 · Cited by 47
Zhou, M., Yuan, J., Deng, Y., Fan, X., & Shen, J. (2021) · Oncogenesis · doi:10.1038/s41389-020-00296-6 · Cited by 49
Hamade, A., Li, D., Tyryshkin, K., Xu, M., Conseil, G., Yolmo, P., Hamilton, J., Chenard, S. W., Siemens, D. R., & Koti, M. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00428-0 · Cited by 43
“Female patients with NMIBC generally present late with more advanced tumor stages than males, and often suffer early recurrences [3–6].”
BackgroundInfluentialB cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
Flippot, R., Teixeira, M., Rey-Cárdenas, M., Carril-Ajuria, L., Rainho, L., Naoun, N., Jouniaux, J.-M., Boselli, L., Naigeon, M., Danlos, F., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008636 · Cited by 52
CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer
Rouanne, M., Arpaia, N., & Marabelle, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.054 · Cited by 44
Immune checkpoint therapy: Forging ahead
Sharma, P., & Allison, J. P. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.adf2947 · Cited by 41
“For example, we identified a combination of two new potential markers—the ARID1A gene mutation in tumor cells and the immune chemokine CXCL13 that drives development of tertiary lymphoid structures in tumor tissues—for selecting patients for ICT (5).”
BackgroundSelf-citationCui, L., Liu, R., Han, S., Zhang, C., Wang, B., Ruan, Y., Yu, X., Li, Y., Yao, Y., Guan, X., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1611 · Cited by 44
“Increasing evidence has suggested that ARID1A can alter the TME and affect immunotherapy sensitivity (3, 8, 42).”
Gu, Y., Zhang, P., Wang, J., Lin, C., Liu, H., Li, H., He, H., Li, R., Zhang, H., & Zhang, W. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03326-x · Cited by 42
Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers
Wang, L., Qu, J., Zhou, N., Hou, H., Jiang, M., & Zhang, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110626 · Cited by 38
Pan, Y., Zhang, J., Xu, C., Liu, F., Cao, J., Chen, Y., Chen, W., & Luo, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643282 · Cited by 42
“reported ARID1A mutation plus CXCL13 expression as composite biomarkers to predict responses to ICI therapy in metastatic UC (13).”
BackgroundSelf-citationKeller, P. J., Adams, E. J., Wu, R., Côté, A., Arora, S., Cantone, N. R., Meyer, R., Mertz, J. A., Gehling, V. S., Cui, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0398 · Cited by 37
“Although ARID1A mutations in certain contexts may predict responses to immunotherapy in metastatic urothelial carcinoma (13), no therapeutic approach has been developed to specifically exploit this potential cancer genomic vulnerability.”
BackgroundPPP2R1A mutations portend improved survival after cancer immunotherapy
Dai, Y., Knisely, A. T., Yano, M., Dang, M., Hinchcliff, E., Lee, S., Welp, A. M., Chelvanambi, M., Lastrapes, M. J., Liu, H., et al. (2025) · Nature · doi:10.1038/s41586-025-09203-8 · Cited by 38
Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites
Muijlwijk, T., Nijenhuis, D. N. L. M., Ganzevles, S. H., Brink, A., Ke, C., Fass, J. N., Rajamanickam, V., Leemans, C. R., Koguchi, Y., Fox, B. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007573 · Cited by 37
Ahmed, J., Das, B., Shin, S. J., & Chen, A. P. (2023) · Cancers · doi:10.3390/cancers15245841 · Cited by 44
“As an example, ARID1A (AT-rich interactive domain-containing protein 1A) mutation is associated with a high TMB and MSI-H tumors, as well as improvement in PFS after ICI therapy [115,116].”
BackgroundARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
Cheng, X., Zhao, J., Dong, F., & Cao, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759577 · Cited by 35
Wang, D., Wang, J., Zhou, D., Wu, Z., Liu, W., Chen, Y., Chen, G., & Zhang, J. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0813 · Cited by 33
“Clinical research has associated SWI/SNF complex alterations with immunotherapy efficacy in urothelial carcinoma (13), pancreatic cancer (16), melanoma (17), and renal cell carcinoma (18, 19).”
Self-citationRoles of ARID1A variations in colorectal cancer: a collaborative review
Zhao, S., Wu, W., Jiang, Z., Tang, F., Ding, L., Xu, W., & Ruan, L. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00469-6 · Cited by 33
“2015). As shown in Fig. 2, the frequency of ARID1A variations among the 23 studies ranged from 3.6% to 66.7%. The mutant type is defined as the loss or low of ARID1A protein expression. Jones et al. (2012), suggested that ARID1A has a tumor suppressor function in the pathogenesis of CRC, and reported that ARID1A expre…”
BackgroundInfluentialTargeting the Tumor-Tumor Microenvironment Crosstalk
Badve, S., & Gökmen‐Polar, Y. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2230362 · Cited by 28
Park, S., Cha, H., Kim, H. S., Lee, B., Kim, S., Kim, T. M., Jung, H. A., Sun, J., Ahn, J. S., Ahn, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5460 · Cited by 30
Current and Emerging Strategies to Treat Urothelial Carcinoma
Rani, B., Ignatz-Hoover, J. J., Rana, P. S., & Driscoll, J. J. (2023) · Cancers · doi:10.3390/cancers15194886 · Cited by 29
Phanthunane, C., Wijers, R., de Herdt, M., Langeveld, T. P. M., Koljenović, S., Dasgupta, S., Sleijfer, S., de Jong, R. J. B., Hardillo, J. A., Balcioglu, H. E., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1882743 · Cited by 28
B cell-related gene signature and cancer immunotherapy response
Lundberg, A., Li, B., & Li, R. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01674-6 · Cited by 29
Chen, X., Li, B., Wang, Y., Jin, J., Yang, Y. Z., Huang, L., Yang, M., Zhang, J., Wang, B., Shao, Z., et al. (2023) · 癌症:英文版 · doi:10.1002/cac2.12465 · Cited by 25
Self-citationFan, T. T., Liu, Y., Liu, H., Wang, L., Tian, H., Zheng, Y., Zheng, B. J., Xue, L., Tan, F., Xue, Q., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02944-1 · Cited by 24
“Although, CXCL2 also promotes immunosuppressive by inducing PD-L1 mRNA expression [45], its high expression correlates with improved overall survival of metastatic urothelial carcinoma by enhancing the sensitivity of tumors to immune checkpoint therapy [46].”
BackgroundARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms
Zhao, S., Xu, Y., Wu, W., Wang, P., Wang, Y., Jiang, H., & Zhu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693295 · Cited by 25
“Mounting evidence suggests ARID1A variation is commonly associated with multiple cancers, including gynecologic cancers, urothelial carcinoma, and gastrointestinal cancer (46, 47), with a mutational rate from 3.”
BackgroundGu, X., Li, D., Wu, P., Zhang, C., Cui, X., Shang, D., Ma, R., Liu, J., Sun, N., & He, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217278 · Cited by 27
Therapeutic significance of ARID1A mutation in bladder cancer
Conde, M., & Frew, I. J. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100814 · Cited by 26
Barakat, R., Chatterjee, J., Mu, R., Qi, X., Gu, X., Smirnov, I., Cobb, O. M., Gao, K., Barnes, A., Kipnis, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54569-4 · Cited by 27
Xu, W., Anwaier, A., Ma, C., Liu, W., Tian, X., Palihati, M., Hu, X., Qu, Y., Zhang, H., & Ye, D. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1908588 · Cited by 23
Self-citationOdnokoz, O., Wavelet-Vermuse, C., Hophan, S. L., Bulun, S. E., & Wan, Y. (2021) · Epigenomics · doi:10.2217/epi-2020-0414 · Cited by 23
Yang, Z., Deng, Y., Cheng, J., Wei, S., Luo, H., & Liu, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695006 · Cited by 21
“Anti-PD-1 therapy failed in a CXCL13-null mouse model of BLCA, whereas the wild-type model showed a good response (59), and the treatment with a combination of CXCL13 and anti-PD-1 successfully retarded tumor growth in another mouse model of OV (60).”
BackgroundAbboud, K., Umoru, G., Esmail, A., Abudayyeh, A., Murakami, N., Al-Shamsi, H. O., Javle, M. M., Saharia, A., Connor, A. A., Kodali, S., et al. (2023) · Cancers · doi:10.3390/cancers15051433 · Cited by 24
Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment
Chaudhri, A., Lizee, G. A., Hwu, P., & Rai, K. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2244 · Cited by 23
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphomaPreprint
Phillips, D. J., Matusiak, M., Rivero‐Gutiérrez, B., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., Fling, S. P., et al. (2020) · medRxiv · doi:10.1101/2020.12.06.20244913 · Cited by 20
Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile
Peng, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.970885 · Cited by 27
“Previous studies have discovered that combinatorial biomarkers (ARID1A mutation plus CXCL13 expression) may improve prediction capability for urothelial carcinoma patients receiving immune checkpoint inhibitors (27), and IL6 may be the most promising predictive biomarker of peptide vaccines for colorectal cancer (28).”
BackgroundHoellwerth, M., Koelblinger, P., Lang, R., & Harrer, A. (2023) · Life · doi:10.3390/life13020553 · Cited by 23
Sarfaty, M., Golkaram, M., Funt, S. A., Al‐Ahmadie, H. A., Kaplan, S., Song, F., Regazzi, A. M., Makarov, V., Kuo, F., Ostrovnaya, I., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02144 · Cited by 21
“Similarly, ARID1A knockdown enhanced sensitivity to ICB in a murine model of bladder cancer.(16) Despite this agreement, further studies are required to evaluate whether this relationship is causative or purely correlative because of the higher mutational load observed in ARID1A-mutated tumors.”
BackgroundResultYolmo, P., Rahimi, S., Chenard, S. W., Conseil, G., Jenkins, D., Sachdeva, K., Emon, I. M., Hamilton, J., Xu, M., Rangachari, M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1114 · Cited by 25
“53, 54).”
Jin, X., Wang, Q., Luo, F., Pan, J., Lu, T., Zhao, Y., Zhang, X., Xiang, E., Zhou, C., Huang, B., et al. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002573 · Cited by 24
“These results suggest that the loss of immunogenicity in urothelial cells is involved in UC development, which may influence the prognosis of patients with UC.”
ResultInfluentialAdaptive Immunity in Genitourinary Cancers
Koti, M., Bivalacqua, T. J., Black, P. C., Cathomen, T., Galsky, M. D., Gulley, J. L., Ingersoll, M. A., Kamat, A. M., Kassouf, W., Siemens, D. R., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.03.002 · Cited by 20
Self-citationSun, D., Teng, F., Xing, P., & Li, J. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00400-5 · Cited by 21
Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective
Lebedev, T. D., Kousar, R., Patrick, B., Usama, M., Lee, M.-K., Tan, M., & Li, X. (2023) · Cells · doi:10.3390/cells12060952 · Cited by 21
“Importantly, combination of ARID1A and CXCL13 in baseline tumor tissues suggested improved overall survival compared to either single biomarker [70].”
BackgroundPauken, K. E., Alhalabi, O., Goswami, S., & Sharma, P. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.005 · Cited by 22
Self-citationCXCL10 could be a prognostic and immunological biomarker in bladder cancer
Yin, T., Mou, S., Zhang, H., Dong, Y., Yan, B., Huang, W., Liu, Y., & Mei, H. (2024) · Discover Oncology · doi:10.1007/s12672-024-00982-6 · Cited by 15
Defects in DNA damage responses in SWI/SNF mutant cells and their impact on immune responses
Begg, K., Braun, H., Ghaddar, N., Wu, L., & Downs, J. A. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103609 · Cited by 18
Xu, S., Li, D., Ning, T., Lu, Y., Sun, Y., Bai, H., Qiao, L., Deng, T., & Liu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1551259 · Cited by 19
Olkhov‐Mitsel, E., Hodgson, A., Liu, S. K., Vesprini, D., Bayani, J., Bartlett, J. M. S., Xu, B., & Downes, M. R. (2022) · Scientific Reports · doi:10.1038/s41598-021-04678-7 · Cited by 15
Is There a Benefit of Combining Immunotherapy and Radiotherapy in Bladder Cancer?
Wilkins, A. C., Ost, P., & Sundahl, N. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.02.014 · Cited by 21
Lamouline, A., Bersini, S., & Moretti, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135401 · Cited by 15
“Immunotherapy has been approved in many cancers, sometimes at stage IV [such as metastatic bladder cancer (26)], and even as a pancancer treatment for the anti-PD1 antibody Pembrolizumab (as long as the cancer has microsatellite instability) (27).”
BackgroundA 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma
Huang, Y., Liao, J., Liang, F., Lin, P., Wu, S., Ye, Y., Gao, M., Chen, R., Zeng, H., Yin, X., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108846 · Cited by 11
Liu, C., Xiao, H., Cui, L., Fang, L., Han, S., Ruan, Y., Zhao, W., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1039631 · Cited by 12
“ARID1A, an AT-rich interactive domain-containing protein 1A, is a component of the switching defective/sucrose non-fermenting (SWI/SNF) complex that plays a role in chromatin remodeling (19), and increasing evidence suggests that ARID1A alterations are correlated with better outcomes after ICI therapy for bladder canc…”
BackgroundThe Role of SWI / SNF Complex in Bladder Cancer
Lei, Z., Han, Y., Liao, J., Li, X., Su, Q., & Yang, Z. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70348 · Cited by 9
Galsky, M. D., Bajorin, D. F., Tomita, Y., Ye, D., Agerbæk, M., Enting, D., Peer, A., Milowsky, M. I., Kobayashi, K., Grimm, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03802-8 · Cited by 12
Self-citationGoswami, S., Siddiqui, B. A., Subudhi, S. K., Basu, S., Yadav, S. S., Diab, A. K., & Sharma, P. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.015 · Cited by 10
Self-citationRole and application of chemokine CXCL13 in central nervous system lymphoma
Li, C., Zhang, L., Jin, Q., Jiang, H., & Wu, C. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05560-4 · Cited by 11
Schaper‐Gerhardt, K., Gutzmer, R., Angela, Y., Zimmer, L., Livingstone, E., Schadendorf, D., Hassel, J. C., Weishaupt, C., Remes, B., Kubat, L., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113984 · Cited by 10
Roznovan, C. N., Marutescu, L. G., & Pîrcălăbioru, G. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136177 · Cited by 13
“For example, mutations in ARID1A and elevated expression of the chemokine CXCL13 have been associated with an improved response to ICI therapy in patients with metastatic urothelial cancer [239].”
The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers
Kalemoglu, E., Jani, Y. C., Canaslan, K., & Bilen, M. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1506278 · Cited by 9
Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets
Stenzinger, A., Kazdal, D. N., & Peters, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.008 · Cited by 8
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC
Cucchiara, F., Crucitta, S., Petrini, I., de Miguel‐Pérez, D., Ruglioni, M., Pardini, E., Rolfo, C. D., Danesi, R., & Re, M. D. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107308 · Cited by 9
Hassan, N., Michaud, E., Mansure, J. J., Farag, M. S., Kool, R., Alessa, M., Sadri, E., Cury, F., Brimo, F., Koti, M., et al. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.09.056 · Cited by 6
Yang, J., Xiong, X., Zheng, W., Xu, H., Liao, X., Wei, Q., & Yang, L. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001939 · Cited by 6
SWI/SNF Alterations in Squamous Bladder Cancers
Achenbach, F., Rose, M., Ortiz‐Brüchle, N., Seillier, L., Knüchel, R., Weyerer, V., Hartmann, A., Morsch, R., Maurer, A., Ecke, T., et al. (2020) · Genes · doi:10.3390/genes11111368 · Cited by 6
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphomaPreprint
Nolan, G. P., Phillips, D. J., Matusiak, M., Rivero‐Gutiérrez, B., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-122285/v1 · Cited by 6
Ma, X., Huang, R., Wu, X., & Zhang, P. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04050-6 · Cited by 5
Differences in genomic profile of high-grade urothelial carcinoma according to tumor location
Park, C. K., & Cho, N. H. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.08.019 · Cited by 5
Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition
Kuo, T., Hou, Y., Shan, Y., Chen, L., & Hung, W. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70394 · Cited by 8
“36 In colorectal cancer, ARID1A -mutated tumours exhibited increased tumour mutational burden, frameshift mutations and higher expression of immune check-point genes.”
Li, Q., Zhang, Z., Wang, Y., Peng, X., Fang, Y., Zhang, Y., Chen, L., Huang, T., Yang, Z., Li, C., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3231 · Cited by 8
Guo, Y. A., Kulshrestha, T., Chang, M. M., Kassam, I., Revkov, E., Rizzetto, S., Tan, A. C., Tan, D. S. W., Tan, I. B., & Skanderup, A. J. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0442 · Cited by 5
“Underlining the validity of our approach, these two genes have been highlighted for their roles in antitumor immunity and association with favorable ICB response in multiple recent studies (16, 58, 59).”
BackgroundResultImmunogenomic precision medicine: a personalized approach based on immunogenomic cancer evolution
Momoi, Y., Kumagai, S., & Nishikawa, H. (2025) · International Immunology · doi:10.1093/intimm/dxaf020 · Cited by 5
Precision Medicine to Treat Urothelial Carcinoma—The Way Forward
Luceno, C. F., Jeon, W. J., Samaeekia, R., Shin, J. H., & Sonpavde, G. (2023) · Cancers · doi:10.3390/cancers15113024 · Cited by 4
“Phase II IMvigor210 [28] Locally advanced or mUC Atezolizumab ARID1A + CXCL13 expression of both ARID1A mutation plus baseline CXCL13 expression had a median OS of 17.”
BackgroundResultInfluentialChenard, S. W., Siemens, D. R., & Koti, M. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00692-x · Cited by 4
Yolmo, P., Rahimi, S., Chenard, S. W., Conseil, G., Jenkins, D., Sachdeva, K., Emon, I. M., Hamilton, J., Xu, M., Rangachari, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.30.522127 · Cited by 4
Lactate Blocks Tertiary Lymphoid Structure Formation by Inhibiting B Cell ChemotaxisPreprint
Boulat, V., Alberts, E., Driscoll, P. C., Hung, M. S., Cunha, A., Quist, J., Liu, F., Brundin, C. A., Bhalla, A., Avalle, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.30.673054 · Cited by 5
Xu, W., Anwaier, A., Liu, W., Tian, X., Qu, Y., Zhao, J., Zhang, H., & Ye, D. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.597 · Cited by 3
Self-citationNeoplasms of the Exocrine Pancreas
Wolff, R. A., Li, D., Maitra, A., Tsai, S., Koay, E. J., & Evans, D. B. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm094.pub2 · Cited by 3
SWI/SNF complex alterations predict immunotherapy response in bladder cancer
Zhang, J., Wang, Y., Yan, Q., Wang, H., Ran, Q., Zhu, H., Luo, W.-M., Ao, Y., Ji, Y. T., Xu, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1708324 · Cited by 3
Self-citation
Metadata
- Authors
- Goswami, S., Chen, Y., Anandhan, S., Szabo, P. M., Basu, S., Blando, J. M., Liu, W., Zhang, J., Natarajan, S. M., Xiong, L., Guan, B., Yadav, S. S., Saci, A., Allison, J. P., Galsky, M. D., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ 08540, USA.
- Bristol-Myers Squibb (United States) (US)
- Tisch Cancer Institute (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-06-17
- Volume
- 12
- Issue
- 548
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3036281565
- Cited by
- 133
- References
- 36
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 21 · 2023: 24 · 2022: 26 · 2021: 29 · 2020: 5
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Parker Institute for Cancer Immunotherapy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- ARID1A mutation, immune checkpoint inhibitors, biomarkers, metastatic urothelial carcinoma, treatment response prediction, overall survival, IMvigor210
- MeSH terms
- Animals, Urinary Bladder Neoplasms, DNA-Binding Proteins, Humans, Mutation, Transcription Factors, Biomarkers, Tumor, Biomarkers, Mice, Chemokine CXCL13, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.